Biofrontera (BFRI)

Executive Summary

Biofrontera Inc. is a U.S.-based commercial-stage biopharmaceutical company focused on dermatology. Its lead product, Ameluz® (aminolevulinic acid) photodynamic therapy (PDT), is FDA-approved for actinic keratosis (AK) and generates the majority of revenue. The company also markets Xepi® (ozenoxacin) for impetigo. Despite having approved products, Biofrontera faces challenges in scaling commercial adoption and achieving profitability, with a market capitalization of approximately $13.7 million. The company's pipeline includes a completed Phase 3 trial for Ameluz in basal cell carcinoma (BCC), which could represent a significant label expansion opportunity if submitted for approval. Other AK-focused studies have been completed, providing potential for formulation enhancements or additional indications. However, the limited pipeline and competitive landscape impose constraints on near-term growth prospects.

Upcoming Catalysts (preview)

• 2025FDA submission for Ameluz in basal cell carcinoma (BCC) following completed Phase 3 data40% success
• TBDPotential strategic partnership or licensing deal to expand Ameluz commercialization30% success
• Q4 2025Quarterly revenue inflection from increased adoption of Ameluz and Xepi50% success